Skip to main
EVAX
EVAX logo

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion AS has shown positive momentum through its deepening partnership with Merck, which recently increased its stake in the company, signaling confidence in Evaxion's AI models and their commercial viability. With the removal of financial overhang from previous quarters, Evaxion is strategically positioned to advance its pipeline, targeting key milestones in 2025 that include pivotal efficacy data and new vaccine candidate announcements. Additionally, the company's successful capital raise of $7.9 million, alongside the compelling advantages of its AI-Immunology platform, further enhances its prospects for innovation and growth in both oncology and infectious diseases.

Bears say

The analysis indicates that Evaxion AS's approach using the AI-Immunology platform may lack significant differentiation in addressing tumor mutation burden (TMB)-low tumors, a segment where existing therapies have demonstrated limited success. This raises concerns about the company's ability to effectively compete in a crowded oncology market, potentially leading to decreased investor confidence. Furthermore, uncertainty regarding the commercial viability of their pipeline products could negatively impact future revenue streams and overall financial stability.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.